---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-014749"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:46:19.072994+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Dogwood Therapeutics Q3 net loss $2.3M; cash runway depends on $3M Feb 2025 tranche

## Summary
- Net loss $2.3M ($2.05/share) vs $1.2M ($1.62) in Q3 2023; R&D and G&A expenses rose.
- Cash $2.0M at Sep 30; $16.5M loan from CKLS affiliate received Oct 7; $3M tranche needed Feb 2025 to fund through 2025.
- Top-line results from IMC-2 Long-COVID Phase 2a study expected mid-November 2024.
- Halneuron Phase 2b CINP interim data expected 2H 2025; FDA fast-track designation granted.
- Company formed via combination of Virios and Pharmagesic; pipeline includes IMC-1, IMC-2, and Halneuron.

## SEC filing metadata
- accession: 0001558370-24-014749
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000155837024014749/0001558370-24-014749-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000155837024014749/viri-20241107x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-014749
- JSON: https://secwatch.observer/filing/0001558370-24-014749.json
- Plain text: https://secwatch.observer/filing/0001558370-24-014749.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.